SPOTLIGHT -
Fredrik Schjesvold, MD, PhD, Discusses the Potential of Minimal Residual Disease –Directed Treatment for Multiple Myeloma
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.
Fredrik Schjesvold, MD, PhD, Discusses Adjustments in the Treatment of Myeloma During the COVID-19 Pandemic
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic impacted the care of multiple myeloma at the Oslo Myeloma Center .
Fredrik Schjesvold, MD, PhD, Discusses the Implications of an FDA Approval for Melflufen in Transplant-Naïve Relapsed/Refractory Multiple Myeloma
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how he would like to see the OCEAN trial and Melflufen progress for relapsed/refractory multiple myeloma.
Fredrik Schjesvold, MD, PhD, Discusses the Safety Profile of Melflufen/Dexamethasone in Relapsed/Refractory Multiple Myeloma
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss the differences in safety profiles between melflufen/dexamethasone and pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Fredrik Schjesvold, MD, PhD, Discusses the Importance of Subgroups When Utilizing Melflufen/Dexamethasone in Relapsed/Refractory Multiple Myeloma
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about importance of subgroups when administering melflufen and dexamethasone to patients with relapsed/refractory multiple myeloma.
Fredrik Schjesvold, MD, PhD, Discusses Key Findings From the OCEAN Trial in Relapsed/Refractory Multiple Myeloma
CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss key data that read out from the OCEAN trial for relapsed/refractory multiple myeloma.
Fredrik Schjesvold, MD, PhD, Discusses the Rationale for the OCEAN Trial in Relapsed/Refractory Multiple Myeloma
Fredrik Schjesvold, MD, PhD, speaks about the FDA approval of melflufen in relapsed/refractory multiple myeloma and its next phase of development at the 2021 International Myeloma Workshop.
